Benzinga | May 26, 2021 09:28AM EDT

VistaGen Kick Starts Late-Stage Social Anxiety Disorder Study with PH94B

* VistaGen Therapeutics Inc (NASDAQ:VTGN) has initiated its PALISADE Phase 3 study to evaluate PH94B for the acute treatment of Social Anxiety Disorder (SAD).

* PH94B is an odorless, rapid-onset, investigational pherine nasal spray.

* PALISADE-1 is being conducted with approximately 200 subjects.

* Topline results from PALISADE-1 are anticipated in mid-2022.

* Price Action: VTGN shares are up 1.35% at $3.01 during the premarket session on the last check Wednesday.